CG OncologyCGON -1.22%12 Market Cap is $6,337.35 Mil as of Jun. 27, 2026. GuruFocus rates CGON with a GF Score™ of 12/100. The stock has 6 warning signs investors should review. Among 1,431 Biotechnology companies, CG Oncology ranks better than 95.6% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). CG Oncology's share price for the quarter that ended in Mar. 2026 was $67.68. CG Oncology's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 88.01 Mil. Therefore, CG Oncology's market cap for the quarter that ended in Mar. 2026 was $5,956.38 Mil.
CG Oncology's quarterly market cap
increased
from Sep. 2025 ($3,153.00 Mil) to Dec. 2025 ($3,350.21 Mil) and
increased
from Dec. 2025 ($3,350.21 Mil) to Mar. 2026 ($5,956.38 Mil).
CG Oncology's annual market cap
increased
from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($2,184.13 Mil) and
increased
from Dec. 2024 ($2,184.13 Mil) to Dec. 2025 ($3,350.21 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. CG Oncology's Enterprise Value for Today is $5,268.68 Mil.
CG Oncology (NAS:CGON) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
CG Oncology Market Cap Related Terms
CG Oncology Market Cap Historical Data
* Premium members only.
The historical data trend for CG Oncology's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CG Oncology's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CG Oncology Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CG Oncology's Market Cap distribution charts can be found below:
* The bar in red indicates where CG Oncology's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
CG Oncology's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CG Oncology (CGON) has a Market Cap of $6,337.35 Mil as of Jun. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on CG Oncology and its competitors. According to the industry distribution chart, CG Oncology ranks #63 out of 1431 companies in the Biotechnology industry, placing it in the top 4.4%.
Is CG Oncology's Market Cap too high?
CG Oncology's current Market Cap is $6,337.35 Mil. The Biotechnology industry median Market Cap is 113.83. CG Oncology's value of $6,337.35 Mil is 5467.6% above this industry median. Based on the distribution chart, CG Oncology ranks #63 out of 1431 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CG Oncology has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does CG Oncology's Market Cap compare to CRSP and XENE?
According to the Biotechnology industry distribution chart, CG Oncology ranks #63 out of 1431 companies for Market Cap. This places CG Oncology in the top 4% of its industry — outperforming the majority of peers. The industry median Market Cap is 113.83. CG Oncology's value of $6,337.35 Mil is 5467.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CG Oncology's current Market Cap of $6,337.35 Mil is 5467.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on CG Oncology and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CG Oncology's current Market Cap is $6,337.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CG Oncology stock overvalued right now?
CG Oncology (CGON) has a current Market Cap of $6,337.35 Mil. The current Market Cap is $6,337.35 Mil and 5467.6% above the Biotechnology industry median of 113.83. CG Oncology's overall GF Score™ is 12/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For CG Oncology (CGON), the current Market Cap is $6,337.35 Mil as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
12GF Score
Get the complete analysis for CGON
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGON has been successfully added to your 
